Artivion (NYSE:AORT) Given “Market Outperform” Rating at JMP Securities

JMP Securities reissued their market outperform rating on shares of Artivion (NYSE:AORT) in a research report report published on Tuesday morning,Benzinga reports. JMP Securities currently has a $33.00 price objective on the stock.

Other analysts have also issued reports about the stock. Stifel Nicolaus increased their price target on shares of Artivion from $28.00 to $30.00 and gave the company a “buy” rating in a research report on Friday, September 13th. Needham & Company LLC reissued a “buy” rating and set a $34.00 target price on shares of Artivion in a research report on Monday. Finally, Oppenheimer raised their target price on shares of Artivion from $30.00 to $32.00 and gave the company an “outperform” rating in a research note on Friday, November 8th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $31.80.

Artivion Trading Down 1.4 %

AORT opened at $29.50 on Tuesday. The company has a current ratio of 1.88, a quick ratio of 1.33 and a debt-to-equity ratio of 0.71. The firm has a market cap of $1.24 billion, a price-to-earnings ratio of -1,475.00 and a beta of 1.75. Artivion has a 12 month low of $16.48 and a 12 month high of $30.45. The stock has a fifty day moving average price of $27.65 and a 200-day moving average price of $26.16.

Insider Activity

In other news, CAO Amy Horton sold 4,329 shares of the firm’s stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $29.66, for a total value of $128,398.14. Following the completion of the transaction, the chief accounting officer now directly owns 135,660 shares in the company, valued at $4,023,675.60. This trade represents a 3.09 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Andrew M. Green sold 7,618 shares of the company’s stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $30.00, for a total value of $228,540.00. Following the completion of the sale, the vice president now owns 33,503 shares in the company, valued at approximately $1,005,090. This represents a 18.53 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 32,447 shares of company stock worth $925,424 over the last 90 days. 8.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Artivion

Institutional investors have recently bought and sold shares of the business. nVerses Capital LLC acquired a new position in shares of Artivion in the 2nd quarter valued at about $28,000. Quarry LP raised its position in Artivion by 210.8% during the third quarter. Quarry LP now owns 1,209 shares of the company’s stock valued at $32,000 after acquiring an additional 820 shares in the last quarter. RiverPark Advisors LLC acquired a new position in Artivion in the second quarter valued at approximately $55,000. RW Investment Management LLC purchased a new stake in Artivion in the 2nd quarter worth approximately $219,000. Finally, Intech Investment Management LLC acquired a new stake in shares of Artivion during the 2nd quarter worth approximately $253,000. 86.37% of the stock is owned by hedge funds and other institutional investors.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.